Form 4: AN2 Therapeutics CFO Lucy Day Sells Shares to Cover Tax Obligations

AN2 Therapeutics' Chief Financial Officer, Lucy Day, sold 2,957 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Lucy Day, the Chief Financial Officer of AN2 Therapeutics, sold 2,957 shares of common stock on January 3, 2025, at a price of $1.341 per share.
• This sale was to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
• Following the transaction, Ms. Day beneficially owns 32,670 shares, which includes 20,625 RSUs that vest over three years from January 1, 2025, and 5,000 shares purchased under the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction for corporate executives to manage their tax liabilities related to equity compensation. It is common for executives to sell shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• The sale of shares by a CFO to cover tax obligations is a common practice across publicly traded companies.
• Many companies use RSUs as part of their compensation packages, and the vesting of these units often triggers tax liabilities for the recipients.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

AN2 Therapeutics, Lucy Day, CFO, stock sale, restricted stock units, RSUs, tax obligations, insider trading, employee stock purchase plan